{"name":"Janux Therapeutics","slug":"janux-therapeutics","ticker":"JANX","exchange":"NASDAQ","domain":"januxrx.com","description":"Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study devel","hq":"La Jolla, CA","founded":0,"employees":"108","ceo":"","sector":"Oncology / Immuno-Oncology","stockPrice":14.57,"stockChange":-0.04,"stockChangePercent":-0.27,"marketCap":"$889M","metrics":{"revenue":13733000,"revenueGrowth":0,"grossMargin":0,"rdSpend":125896000,"netIncome":-113625000,"cash":956385984,"dividendYield":0,"peRatio":-5.2,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOYlJNNjJMdkdsekpoS3h2TDFIWWZZRGtZdnRGcXQ1V2ZjbjFOMERqWG1peTRWcUd0WGtILTBGWHpOWGhFLU0wejJDRlVVLVhBcTZxT1VSS0hOSW9JcVp2REJISld1YTktaHBZcmp0dHZ2ZXpPSkpqaV9mQWhIZkZ4NEVGYmZyY2FOZmlsbUdhZ2pjY0hNRGJyVTR5YmFET0o0NjFCWlpKTXZhcjIyWTltMVk1T01HdmJQYlE?oc=5","date":"2026-04-02","type":"deal","source":"TradingView","summary":"Janux Therapeutics Secures $35M Milestone Payment From BMY Deal - TradingView","headline":"Janux Therapeutics Secures $35M Milestone Payment From BMY Deal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"pipeline","source":"simplywall.st","summary":"Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives - simplywall.st","headline":"Janux Therapeutics JANX Net Loss Deepens To US$113.6 Million Challenging Bullish Growth Narratives","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQQzZkb2lheGQzMVVLZVQ0ZXdnV0FqZ1VacHRHZERjOXJYZE9QR05mMzFLS2dJR1lXRDdHWFV3cndkOGV6UGtSZGpJTW9ENkZwbjV0OG1XdGhMcjV5YXl1MExhUGRwTGtYcHNNeEZMYnNCdmQ1QXkwZWJXTlNBanBhdk9nbzhkVHY1U1YtVlhvX01yaTQzQWtWdlFRMkt5SWZZZTc4Wmx5eHFQZUhBejByQThSeWVXdy1JZXg4YlRJY1R6WWM?oc=5","date":"2026-02-25","type":"deal","source":"San Diego Business Journal","summary":"Janux T Cell Engagers Attract Bristol Myers Squibb Development Deal - San Diego Business Journal","headline":"Janux T Cell Engagers Attract Bristol Myers Squibb Development Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOaDJKblJ2Y3MycEM5LWt1cm5QWXBkSllland2eVZ5OUp6ZFdRdjVEWWJXakd5a0VlellzZlZYUmJvQXpYMy00XzE2aW8wOGRDSWlVcHp2LW5FdnhkYmI3S1JzWHNrNlBSNTNKZ1lSRHV5NUI3S0o1MFVibl90WWUtaXpJWGRTeWdxTVVMYTllZGZIOHJ0NllqWGhudmo4SmlpMDVSXzdlUFVPXzZ1QkwxdFAxXzdNRU0?oc=5","date":"2026-02-16","type":"pipeline","source":"24/7 Wall St.","summary":"Wall Street Thinks These 4 Biotech Stocks Will Double--At Least--This Year - 24/7 Wall St.","headline":"Wall Street Thinks These 4 Biotech Stocks Will Double--At Least--This Year - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPQ0JCT3d3STRGaFQ2LUdMMnNLRVVLbjNVTDQwTTV3RENtNUZVVnZmMWNEODVSSmF6eEVGNnNRUXRhWHRJc3pCVU9oZFlFR3Q4T2hvNWVKdWpOUFc2Vy0tdjlFbGNQR0FUUUhmYTNnVmpMLWYwZ3lhOElEempjTEp3QzZnc19Na2tGd3BZZ2xhVGwxSjJNRzFKQXlGeEZnVEF0V1Z2NGdxRUFHOEVq?oc=5","date":"2026-01-26","type":"pipeline","source":"Contract Pharma","summary":"Janux Therapeutics Taps Dr. William Go as Chief Medical Officer - Contract Pharma","headline":"Janux Therapeutics Taps Dr. William Go as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNWkZJbTFkU0xpSzFyRzdLbnJVOXliSjlMdVNvTkxQcHZFdWtYb3NnQW5IajRGeVd6UVJzYTBLdkJMQlBKQURNSEtVYWttNXRHSGlXZnVnTXpxU09uTkhJUXRPa2FlWXgzcWZKdEdsV2ZjcHlqenRTUXNsWE8ydzlHR0llRkJvRnM2ZF9LbElDSjBoWEJtb2pIeUtEZkpLOVJuaVZGT3lRUWlIejBISWRYU0dnTFE4QnBVZXhhSUFQQ3A2RS1qT2tfMmxTQQ?oc=5","date":"2026-01-26","type":"pipeline","source":"Business Wire","summary":"Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire","headline":"Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOaGx5TUVKTWY0YXIwWHFHX0hUam00aHhJZmpzN3Q0b3EtUkFHcFlpX0xBVGxuYkdlV2RBeEtKMUxoUHBwLUhzdm9wbERqWlhpS3BNVlVMd1ozcWk3WjRmY3B3U3BHb1VrQ1VkN0JIUFhrWGZET3Z1RU9XanZ3Ym1TZEo1dWdDS0hrT0lLaUI3OFFDMmVPT3ZrdFB3?oc=5","date":"2026-01-23","type":"deal","source":"The Pharma Letter","summary":"Janux Therapeutics rises on license deal with BMS - The Pharma Letter","headline":"Janux Therapeutics rises on license deal with BMS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQaTFnSHo5eWpqdWtkd2JTdm9VSEtPdUJvd3dDUlNOanVpZkZTSHR3MnRsSF9xQlRSeVFHM3lXaGFoMGZlNGFFWm94RWxfMUoxeUtPZjJYaUN4RlpPcWhfa1MxZ3VfRmxYaVpwTnlSZExmc1Q1TUlMbHE2SUtsaFhVMjZ1M2dBa2VUVmVkZnVjWWt1WE1pRHdVeHlaTzVlWXJqVmprc0c0cmcxN2pVdmliYVh3?oc=5","date":"2026-01-22","type":"deal","source":"Pharmaceutical Technology","summary":"BMS bets on Janux’s novel solid tumour therapy through $850m deal - Pharmaceutical Technology","headline":"BMS bets on Janux’s novel solid tumour therapy through $850m deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNckl2S0RUTEJvV2VpU3I4clptMFdyalItY1g3MEh4emhmeUNQd1M1ODk1Ull3VnFVWU5ON3dFQ09Ta1RKbndVb1JtRXBPX2RlalZqQkN2R2pvWG9kME9HQkNLWGI5MnQ3SWZyQ05BTDdqTWpqOXlMYkJMS1U3SXNjOTd1ZGdtaTlMMThyMEVUVjhyZlpLSTdkUUFZRWFyemlCcTBfa0NXdDJHZi1ibm5CRThfZTNkblE4Mkt3MEotWHFYRURjQVNJX1I5WWxPRGZoSndxQm1wNzEyMTM0WFVBbEJaS2M?oc=5","date":"2026-01-22","type":"deal","source":"Reuters","summary":"Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters","headline":"Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPcVVHX2c2R3ZheWtnRmlpdnFXVUFlUnV1d2FyelBnUzVEQ2tqVkU2MDVVbWdsNGhkZmNxVTNOR3RRbGxMSzN0bjBYSUpaREdTLUhRSXdqVFJicWZVanIwUWRsdlplbVZQdUdvT3c3OWt1VnphTTNjT2hxSUdZMm02a0prMWVjZ0RQNWNacXVYRUVLUWJzWGJFU24xZHQwZw?oc=5","date":"2026-01-22","type":"pipeline","source":"Fierce Biotech","summary":"BMS pens $850M solid tumor pact with T-cell engager biotech Janux - Fierce Biotech","headline":"BMS pens $850M solid tumor pact with T-cell engager biotech Janux","sentiment":"neutral"},{"date":"2026-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPZXp6WksxU2J3VVkyNGMyT1ZlMXhDTko4YVFsSjYxcDJ2SVV3WFNEakc3Q21nZFhSNmw3VnhfNmpWSDJmNkRPQmUyd2VCcGdIMXFsRnpYN3hrWmhuZnljYzUwUWVDeDRUeDNhQ0lvYzdEYXRjVkdHZk1Ka1ZHUmxqNnpCdW9yZFZJQXRKU05aLTNaX2RyLWVMUQ?oc=5","date":"2025-12-02","type":"trial","source":"Barron's","summary":"Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Barron's","headline":"Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Barron's","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9lYjNCNXB0M1dfXzVqMHZmcWFxZF9OOVdxZGN2YjV5dUlZM0FmNl9PSDBNYjJYUU05dTFDLXJHR1Bnc3B2alY5allJNXZDQkhKa1pZ?oc=5","date":"2025-12-02","type":"pipeline","source":"FirstWord Pharma","summary":"Janux shares halved on new prostate cancer results - FirstWord Pharma","headline":"Janux shares halved on new prostate cancer results","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":10000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":10000000},{"period":"2024-12-31","value":10588000},{"period":"2023-12-31","value":8083000},{"period":"2022-12-31","value":8612000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":125896000,"rdSpendHistory":[{"period":"2025-12-31","value":125896000},{"period":"2024-12-31","value":68388000},{"period":"2023-12-31","value":54922000},{"period":"2022-12-31","value":53441000}],"sgaSpend":41771000,"operatingIncome":-157667000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-157667000},{"period":"2024-12-31","value":-98847000},{"period":"2023-12-31","value":-72979000},{"period":"2022-12-31","value":-67091000}],"netIncome":-113625000,"netIncomeHistory":[{"period":"2025-12-31","value":-113625000},{"period":"2024-12-31","value":-68994000},{"period":"2023-12-31","value":-58293000},{"period":"2022-12-31","value":-63059000}],"eps":-1.28,"epsHistory":[{"period":"2024-12-31","value":-1.28},{"period":"2023-12-31","value":-1.32},{"period":"2022-12-31","value":-1.52},{"period":"2021-12-31","value":-1.39}],"cash":52334000,"cashHistory":[{"period":"2025-12-31","value":52334000},{"period":"2024-12-31","value":430605000},{"period":"2023-12-31","value":19205000},{"period":"2022-12-31","value":51426000}],"totalAssets":1001565000,"totalLiabilities":44743000,"totalDebt":22139000,"equity":956822000,"operatingCashflow":-82235000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-82235000},{"period":"2024-12-31","value":-43814000},{"period":"2023-12-31","value":-50575000},{"period":"2022-12-31","value":-42922000}],"capex":-1043000,"capexHistory":[{"period":"2025-12-31","value":-1043000},{"period":"2024-12-31","value":-359000},{"period":"2023-12-31","value":-1850000},{"period":"2022-12-31","value":-6445000}],"freeCashflow":-83278000,"dividendsPaid":null,"buybacks":-347000,"employees":108,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":10853000,"ebit":-42401000,"ebitda":-41933000,"period":"2025-12-31","revenue":0,"epsBasic":-0.51,"netIncome":-31946000,"rdExpense":31548000,"epsDiluted":-0.51,"grossProfit":null,"operatingIncome":-42401000},{"sga":10622000,"ebit":-35251000,"ebitda":-34750000,"period":"2025-09-30","revenue":10000000,"epsBasic":-0.39,"netIncome":-24313000,"rdExpense":34629000,"epsDiluted":-0.39,"grossProfit":null,"operatingIncome":-35251000},{"sga":10454000,"ebit":-45118000,"ebitda":-44577000,"period":"2025-06-30","revenue":0,"epsBasic":-0.55,"netIncome":-33858000,"rdExpense":34664000,"epsDiluted":-0.55,"grossProfit":null,"operatingIncome":-45118000},{"sga":9842000,"ebit":-34897000,"ebitda":-34378000,"period":"2025-03-31","revenue":0,"epsBasic":-0.38,"netIncome":-23508000,"rdExpense":25055000,"epsDiluted":-0.38,"grossProfit":null,"operatingIncome":-34897000},{"sga":8216000,"ebit":-29022000,"ebitda":-28510000,"period":"2024-12-31","revenue":0,"epsBasic":-0.36,"netIncome":-20216000,"rdExpense":20806000,"epsDiluted":-0.36,"grossProfit":null,"operatingIncome":-29022000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.57,"previousClose":14.61,"fiftyTwoWeekHigh":35.34,"fiftyTwoWeekLow":12.12,"fiftyTwoWeekRange":"12.12 - 35.34","fiftyDayAverage":14.42,"twoHundredDayAverage":19.29,"beta":2.57,"enterpriseValue":-43833588,"forwardPE":-5.2,"priceToBook":0.94,"priceToSales":64.7,"enterpriseToRevenue":-3.19,"enterpriseToEbitda":0.28,"pegRatio":0,"ebitda":-155004000,"ebitdaMargin":0,"freeCashflow":-54010376,"operatingCashflow":-77548000,"totalDebt":21571000,"debtToEquity":2.3,"currentRatio":17.01,"returnOnAssets":-9.4,"returnOnEquity":-11.7,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":16,"targetMeanPrice":40.56,"targetHighPrice":80,"targetLowPrice":14,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":6.7,"institutionHeldPercent":108.2,"sharesOutstanding":60984354,"floatShares":38755557,"sharesShort":7932981,"shortRatio":7.94,"shortPercentOfFloat":13,"epsTrailing":-1.84,"epsForward":-2.81,"revenuePerShare":0.22,"bookValue":15.47,"officers":[{"age":65,"name":"Dr. David Alan Campbell Ph.D.","title":"President, Co-Founder, CEO & Director"},{"age":39,"name":"Dr. Thomas  Diraimondo Ph.D.","title":"Chief Scientific Officer"},{"age":47,"name":"Ms. Janeen  Doyle","title":"Chief Corporate & Business Development Officer"},{"age":null,"name":"Mr. Matt  Whitmire","title":"Vice President of Finance"},{"age":35,"name":"Ms. Maria  Dobek","title":"Vice President of Accounting"},{"age":56,"name":"Mr. Charles M. Winter","title":"Chief Technical Officer"},{"age":null,"name":"Mr. James  Pennington","title":"General Counsel & Corporate Secretary"},{"age":49,"name":"Dr. William Y. Go M.D., Ph.D.","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.januxrx.com","phone":"858 751 4493"}}